‘Absolutely remarkable’: HCPs tweet excitement for study of dostarlimab in rectal cancer

Calling the research “beyond impressive” and “absolutely remarkable,” HCPs took to Twitter to heap praise on study results presented at the ASCO Annual Meeting describing treatment with dostarlimab in a subset of rectal cancer patients.As Healio previously reported, dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer in the phase 2 study.Marco Gerlinger (@MarcoGerlinger) June 5, 2022. Andrea Cercek LBA at #ASCO22 14 of 14 (100%)Read More

Related Articles